CTMX Fundamental Analysis - CYTOMX THERAPEUTICS INC

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to CTMX. CTMX was compared to 534 industry peers in the Biotechnology industry. CTMX has an excellent financial health rating, but there are some minor concerns on its profitability. CTMX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CTMX was profitable.

CTMX had a negative operating cash flow in the past year.

In the past 5 years CTMX reported 4 times negative net income.

CTMX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

CTMX has a better Return On Assets (27.41%) than 97.94% of its industry peers.

With an excellent Return On Equity value of 40.02%, CTMX belongs to the best of the industry, outperforming 98.13% of the companies in the same industry.

CTMX's Return On Invested Capital of 25.08% is amongst the best of the industry. CTMX outperforms 98.13% of its industry peers.

		Industry Rank	Sector Rank
ROA	27.41%
ROE	40.02%
ROIC	25.08%

ROA(3y)-3.97%

ROA(5y)-11.04%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CTMX has a better Profit Margin (34.01%) than 96.63% of its industry peers.

With an excellent Operating Margin value of 30.56%, CTMX belongs to the best of the industry, outperforming 96.82% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	30.56%
PM (TTM)	34.01%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CTMX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.

The number of shares outstanding for CTMX has been increased compared to 1 year ago.

The number of shares outstanding for CTMX has been increased compared to 5 years ago.

There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CTMX has an Altman-Z score of 3.85. This indicates that CTMX is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of CTMX (3.85) is better than 70.97% of its industry peers.

There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.85

ROIC/WACC2.68

WACC9.37%

2.3 Liquidity

CTMX has a Current Ratio of 4.20. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.

CTMX has a Current ratio (4.20) which is in line with its industry peers.

CTMX has a Quick Ratio of 4.20. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 4.20, CTMX is in line with its industry, outperforming 49.63% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.2
Quick Ratio	4.2

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CTMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 306.43%, which is quite impressive.

CTMX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.01%.

Measured over the past years, CTMX shows a quite strong growth in Revenue. The Revenue has been growing by 19.15% on average per year.

EPS 1Y (TTM)306.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.75%

Revenue 1Y (TTM)18.01%

Revenue growth 3Y54.7%

Revenue growth 5Y19.15%

Sales Q2Q%-25.71%

3.2 Future

The Earnings Per Share is expected to decrease by -51.75% on average over the next years. This is quite bad

Based on estimates for the next years, CTMX will show a decrease in Revenue. The Revenue will decrease by -0.20% on average per year.

EPS Next Y-91.46%

EPS Next 2Y-67.9%

EPS Next 3Y-45.06%

EPS Next 5Y-51.75%

Revenue Next Year-23.36%

Revenue Next 2Y-40.29%

Revenue Next 3Y-33.54%

Revenue Next 5Y-0.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 6.34, the valuation of CTMX can be described as very cheap.

Based on the Price/Earnings ratio, CTMX is valued cheaply inside the industry as 98.13% of the companies are valued more expensively.

The average S&P500 Price/Earnings ratio is at 27.69. CTMX is valued rather cheaply when compared to this.

CTMX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	6.34
Fwd PE	N/A

4.2 Price Multiples

97.57% of the companies in the same industry are more expensive than CTMX, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	7.82

4.3 Compensation for Growth

CTMX's earnings are expected to decrease with -45.06% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-67.9%

EPS Next 3Y-45.06%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CTMX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (10/21/2025, 4:00:51 PM)

After market: 3.615 0 (0%)

3.615

-0.12 (-3.34%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-07 2025-08-07/amc

Earnings (Next)11-06 2025-11-06/amc

Inst Owners78.75%

Inst Owner Change0.59%

Ins Owners0.6%

Ins Owner Change3.95%

Market Cap596.15M

Analysts84.29

Price Target5.9 (63.21%)

Short Float %19.93%

Short Ratio8.2

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)106.1%

Min EPS beat(2)98.72%

Max EPS beat(2)113.47%

EPS beat(4)4

Avg EPS beat(4)141.82%

Min EPS beat(4)98.72%

Max EPS beat(4)215.22%

EPS beat(8)8

Avg EPS beat(8)146.11%

EPS beat(12)10

Avg EPS beat(12)101.81%

EPS beat(16)11

Avg EPS beat(16)73.27%

Revenue beat(2)2

Avg Revenue beat(2)42.82%

Min Revenue beat(2)23.76%

Max Revenue beat(2)61.87%

Revenue beat(4)4

Avg Revenue beat(4)66.28%

Min Revenue beat(4)23.76%

Max Revenue beat(4)92.34%

Revenue beat(8)8

Avg Revenue beat(8)60.6%

Revenue beat(12)10

Avg Revenue beat(12)36.87%

Revenue beat(16)10

Avg Revenue beat(16)12.56%

PT rev (1m)0.62%

PT rev (3m)5.19%

EPS NQ rev (1m)-5.79%

EPS NQ rev (3m)39.73%

EPS NY rev (1m)89.94%

EPS NY rev (3m)115.37%

Revenue NQ rev (1m)-3.12%

Revenue NQ rev (3m)-1.06%

Revenue NY rev (1m)-0.79%

Revenue NY rev (3m)5.59%

Valuation

		Industry Rank	Sector Rank
PE	6.34
Fwd PE	N/A
P/S	4.23
P/FCF	N/A
P/OCF	N/A
P/B	4.97
P/tB	5.03
EV/EBITDA	7.82

EPS(TTM)0.57

EY15.77%

EPS(NY)-0.32

Fwd EYN/A

FCF(TTM)-0.47

FCFYN/A

OCF(TTM)-0.47

OCFYN/A

SpS0.86

BVpS0.73

TBVpS0.72

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	27.41%
ROE	40.02%
ROCE	31.75%
ROIC	25.08%
ROICexc	N/A
ROICexgc	N/A
OM	30.56%
PM (TTM)	34.01%
GM	N/A
FCFM	N/A

ROA(3y)-3.97%

ROA(5y)-11.04%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.81

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	0
Cap/Depr	15.57%
Cap/Sales	0.17%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.2
Quick Ratio	4.2
Altman-Z	3.85

F-Score6

WACC9.37%

ROIC/WACC2.68

Cap/Depr(3y)42.33%

Cap/Depr(5y)55.65%

Cap/Sales(3y)1.42%

Cap/Sales(5y)2.17%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)306.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.75%

EPS Next Y-91.46%

EPS Next 2Y-67.9%

EPS Next 3Y-45.06%

EPS Next 5Y-51.75%

Revenue 1Y (TTM)18.01%

Revenue growth 3Y54.7%

Revenue growth 5Y19.15%

Sales Q2Q%-25.71%

Revenue Next Year-23.36%

Revenue Next 2Y-40.29%

Revenue Next 3Y-33.54%

Revenue Next 5Y-0.2%

EBIT growth 1Y654.07%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year309.72%

EBIT Next 3Y-10.1%

EBIT Next 5YN/A

FCF growth 1Y-48.81%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-51.83%

OCF growth 3YN/A

OCF growth 5YN/A

CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens